Centers | ||
|
|
|
Therapeutic Accelerator Program (TAP) | Chemical Genomics Facility at Purdue Institute for Drug Discovery | EU-OPENSCREEN |
Test |
The Chemical Genomics Facility is a core facility at Purdue Institute for Drug Discovery that provides expertise and resources needed in the early stage of drug discovery. The services include small molecule libraries, access to automated equipment... Read more |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Sanofi and Weill Cornell Medical College to Discover New Drus to Treat TuberculosisSanofi has entered into a new collaboration with Dr.Carl Nathan's laboratory at Weill Cornell Medical College to screen existing compounds and develop new compounds to shorten the course of treatment of tuberculosis and increase effectiveness of... View all Novo Nordisk and Oxford to Develop Drugs to Treat Rheumatoid Arthritis and Other Inflammatory DiseasesNovo Nordisk and Kennedy Institute of Rheumatology at Oxford University have entered into partnership to develop new drugs to treat Rheumatoid Arthritis and other inflammatory disorders. Novo Nordisk will provide research funding support to ten... View all |
No EVENTS for listing |
No Job Posts |
